Global Stem Cells Group Partners with StemBio to Advance Regenerative Medicine Research and Development
Miami, Florida— Global Stem Cells Group, a leader in regenerative medicine, is thrilled to announce a strategic partnership with StemBio, a renowned leader in the regenerative medicine landscape in Turkey. This partnership aims to propel research and development, conduct clinical trials, and create new products and protocols for the advancement of regenerative medicine.
StemBio, a trailblazer in Turkey, possesses all the necessary licenses and state-of-the-art infrastructure for regenerative medicine, including Bone Marrow Derived MSC, Adipose Derived MSC, Umbilical cord, placenta, Wharton jelly Derived MSC, Synovial Derived MSC, and more. We believe this diverse range of resources demonstrates StemBio’s commitment to excellence, making them one of the foremost facilities for regenerative medicine in Turkey.
This collaboration brings together two powerhouses in the regenerative medicine arena, aiming to break new ground in the research, development, and application of regenerative therapies. We believe the collective expertise and resources of StemBio and Global Stem Cells Group are set to drive innovation and advancements in regenerative care, benefiting patients worldwide.
“We are excited to partner with StemBio and leverage their expertise in regenerative medicine. This partnership should accelerate our mission to provide cutting-edge regenerative solutions to a global audience,” said Benito Novas, head of relationships at Global Stem Cells Group.
We believe the partnership between StemBio and Global Stem Cells Group signifies a significant milestone in the regenerative medicine field. As they combine their strengths and knowledge, they are committed to pushing the boundaries of what is possible in regenerative care and making a lasting impact on patients’ lives.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
About StemBio:
StemBio is a renowned regenerative medicine facility in Turkey, equipped with cutting-edge infrastructure and a commitment to excellence. Holding the necessary licenses for cord blood and tissue banking, as well as advanced engineering solutions, StemBio is a leader in the regenerative medicine landscape.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in News
Global Stem Cells Group and ReGen Inaugurate New Franchise Clinic in Tashkent, Uzbekistan
Global Stem Cells Group (GSCG) and ReGen are thrilled to announce the grand opening of a new franchise clinic in Tashkent, Uzbekistan. The inauguration ceremony, attended by distinguished leaders in the field of regenerative medicine, marks a momentous occasion for healthcare in the region.
The event was graced by the presence of Dr. Salih Yildirim, Director of ReGen and President of the International Society for Stem Cell Application (ISSCA), and Benito Novas, the Director of Public Relations for both GSCG and ISSCA.
In addition to celebrating the clinic’s opening, the Tashkent center hosted the first ISSCA training program in the region, providing local physicians with the latest advancements in regenerative medicine.
Dr. Salih Yildirim expressed his delight, stating, “After inaugurating clinics in Istanbul (Turkey), Buenos Aires (Argentina), Cancun (Mexico), Miami (USA), and Jakarta (Indonesia), we are now here in Uzbekistan, in Tashkent. This moment fills me with great joy and a profound sense of purpose. It is a privilege to bring the benefits of regenerative medicine to the people of Uzbekistan”
Benito Novas added, “This is impressive. In the field of regenerative medicine, we aim to expand the movement, benefiting not only local patients but patients worldwide. This will undoubtedly be a great success. Regenerative medicine is not just the medicine of the future; it’s the medicine of the present.”
The newly established center will also serve as a training hub for ISSCA, contributing to the enhancement of knowledge and expertise among healthcare professionals in the region.
Partnership Between Global Stem Cells Group and ReGen
Through their strategic partnership, ReGen has experienced remarkable growth, leveraging Global Stem Cells Group’s reputation and extensive resources to open state-of-the-art clinics in several countries. These clinics have become pioneers in regenerative care in the region.
ReGen is at the forefront of introducing cutting-edge aesthetic treatments, such as the perfected hair transplant technique from Turkey, revolutionizing the regenerative healthcare landscape. Patients now have access to the latest and most effective treatment options. This partnership underscores Global Stem Cells Group’s vision to make its exceptional services accessible to people around the world.
While ReGen brings access to clinics, advanced techniques and expertise, Global Stem Cells Group provides valuable resources as a conglomerate of companies engaged in product manufacturing and comprehensive training through ISSCA. This collaboration has the potential to change the lives of people seeking regenerative care on a global scale.
This landmark partnership is poised to reshape the world of regenerative care, marking a transformative moment for the field of regenerative medicine.
For more information about Global Stem Cells Group and its regenerative medicine solutions, please visit https://www.stemcellsgroup.com/.
About Global Stem Cells Group
Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.
About ReGen
ReGen is a highly acclaimed Turkish company with clinics in Turkey and in several other locations around the world, renowned for its expertise in cutting-edge technologies related to regenerative care. Headquartered in Istanbul, ReGen has gained international recognition for its commitment to excellence and its groundbreaking advancements in regenerative medicine. By partnering with Global Stem Cells Group, ReGen aims to share its advanced techniques and expertise on a global scale, improving access to regenerative care and transforming lives worldwide.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
For further information, please contact:
investor.relations@mssvinc.com
Telephone: (800) 956-3935
- Published in News
ISSCA Extends Regenerative Medicine World Congress 2023 with Additional Hands-On Experience Day
Miami, Florida – The International Society for Stem Cell Application (ISSCA) is pleased to announce a new date for practical certification at the highly anticipated 2023 World Congress of Regenerative Medicine in Istanbul, Turkey. Due to the overwhelming demand for clinical experience with real patients, ISSCA has extended the event, providing doctors with an extra day of hands-on training.
The original three-day event, scheduled from November 10 to 12, 2023, includes two days of stimulating conferences and lectures on November 10 and 11, conducted by distinguished physicians from around the world. This covers subjects pertinent to basic science, current advancements, and clinical experiences.
Due to an unprecedented response, the hands-on clinical experience day, November 12, is already at full capacity for the initial package subscribers. However, ISSCA has made the prudent decision to open a new date for training on November 13, 2023. This additional date offers an opportunity for new participants to benefit from valuable hands-on experience while also participating in the two days of conferences on November 10 and 11.
To facilitate a comprehensive understanding of the training and certification programs offered during the World Congress, ISSCA has launched a dedicated website showcasing agendas for various days and different package options. For more information, please visit https://www.issca.us/turkey-world-conference-2023/.
What to Expect at the ISSCA World Congress of Regenerative Medicine
The ISSCA World Congress of Regenerative Medicine serves as a global platform for the advancement of cellular therapies, related technologies, and clinical applications. This annual gathering brings together eminent scientists and physicians from over 30 countries for three days of conferences, lectures, and hands-on clinical application workshops.
Key focus areas for this year’s event include:
- Molecular Biology
- New treatment models in surgical and cosmetic applications
- The latest innovations in regenerative Medicine
Furthermore, the conference will explore the legal implications of regenerative medicine practices worldwide.
A Transformative Experience
The ISSCA 2023 World Congress in Istanbul is a must-attend event for all those interested in regenerative medicine. Focused on innovation, collaboration and knowledge sharing, the congress expects to be a transformative experience for scientists, physicians and healthcare professionals from around the world.
For more information about the November 10 to 13 ISSCA World Congress 2023, please visit our official website today.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in News
ISSCA Announces Partnership with Turkish Stem Cell Society and Endorsement by Leading Turkish Universities for Regenerative Medicine Congress
Miami, Florida – The International Society for Stem Cell Application (ISSCA) is delighted to announce its strategic partnership with the Turkish Stem Cell Society, along with the prestigious endorsement of three of Turkey’s top universities: Yeditepe University, Atlas University and Marmara University. This collaboration marks a significant milestone in advancing the field of regenerative medicine and stem cell therapy in Turkey and beyond.
The annual Congress of Regenerative Medicine, scheduled to take place from November 10 to 12, 2023, will be hosted at the elegant Crowne Plaza Istanbul Florya Hotel in Istanbul, Turkey. This event is poised to serve as a pivotal platform for the exchange of groundbreaking advancements in stem cell therapy and regenerative medicine.
Partnership with Turkish Stem Cell Society and University Endorsements
The partnership with the Turkish Stem Cell Society underscores the commitment of ISSCA to advancing the field of regenerative medicine not only on a global scale but also within the vibrant Turkish scientific and medical community. Turkish Stem Cell Society has been at the forefront of research and innovation in stem cell therapy, making this collaboration a natural fit to foster greater knowledge sharing and cooperation.
Furthermore, ISSCA is honored to be endorsed by three of the most prestigious universities in Turkey:
Yeditepe University: Yeditepe University, a leading academic institution in Turkey, has a rich history of contributing to the fields of medicine and healthcare. Its endorsement of the Regenerative Medicine World Congress 2023 reaffirms the importance of this event in advancing the understanding of regenerative medicine.
Atlas University: Atlas University, with its commitment to research and innovation, plays a pivotal role in shaping the future of healthcare in Turkey. The university’s endorsement signifies the importance of regenerative medicine in modern medical practices.
Marmara University: Marmara University, recognized for its commitment to excellence in education, research, and innovation, is yet another prestigious institution supporting the congress. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, Marmara University has become a center of intellectual discovery and academic achievement. The university’s renowned faculty and state-of-the-art infrastructure collaborate with Global Stem Cells Group to drive advances in regenerative medicine within the center, which is located on the university’s main campus.
World Congress Highlights
Representing over 35 countries, the Regenerative Medicine World Congress 2023 is set to be a hub of medical expertise. Renowned doctors and scientists from around the globe are expected to converge to share their insights and findings through evidence-based research presentations. This three-day symposium is designed to reshape medical understanding and ignite innovative possibilities.
A key feature of the congress is the immersive hands-on training, provided by ISSCA-certified instructors. Participants are expected to have the opportunity to delve into clinical and aesthetic applications of stem cell therapy over a single intensive day. This specialized training, guided by experts with extensive experience, equips attendees with practical skills that can be directly applied in their medical practice.
Collaboration and Appreciation
ISSCA is thrilled about the collaborative partnership with the Turkish Stem Cell Society and deeply appreciates the endorsements from Yeditepe University, Atlas University, and Marmara University. We look forward to the Regenerative Medicine World Congress 2023 as a significant step towards advancing the field of regenerative medicine. Your support and participation are invaluable, and we are genuinely excited to embark on this journey together.
For more information about the Regenerative Medicine World Congress 2023 and to register for this groundbreaking event, please visit www.issca.com
About the Turkish Stem Cell Society:
The Turkish Stem Cell Society is a leading organization dedicated to promoting ethical and responsible stem cell research and therapy in Turkey. They are committed to advancing scientific knowledge and education in the field of stem cells and regenerative medicine.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in News
Beyond Boundaries: How Stem Cells Are Reshaping Organ and Tissue Transplantation
Within the sacred corridors of medical advancement, a profound transformation is silently taking place, poised to reshape the very foundations of organ and tissue transplantation. Envision a realm where donor shortages and the specter of immune system rejection fade into history, and where medical horizons stretch to unprecedented frontiers. In this immersive voyage, we embark on a journey to unmask the enigmatic power of stem cells in the realm of transplantation, a journey that invites you to witness the precipice of medical progress.
Stem Cells: Pioneers of Regeneration
Stem cells, those remarkable architects of the body’s rejuvenation, harbor an astonishing talent for metamorphosis, seamlessly transforming into diverse cell types to mend and invigorate damaged tissues. When seamlessly integrated into the landscape of organ and tissue transplantation, stem cells open a tantalizing path towards surmounting the inherent complexities of these procedures. Whether it’s breathing vitality into faltering heart muscles, reviving the compromised functionality of a beleaguered liver, or revitalizing lungs beset by adversity, stem cells emerge as the harbinger of transformation for transplantation outcomes.
The Choreography of Compatibility
Navigating the intricate choreography of compatibility between donor and recipient is one of the most formidable tasks in transplantation. The ever-watchful immune system often triggers rejection, undermining even the most meticulous transplantation endeavors. Yet, stem cells are orchestrating a symphony of change. Through ingenious techniques, researchers are tapping into stem cells’ immunomodulatory prowess, crafting an environment of harmonious coexistence between donor and recipient. This revolutionary approach not only mitigates the risks of rejection but also broadens the spectrum of viable donors.
A Symphony of Science
The harmony between stem cells and transplantation is not an untested hypothesis; it’s a symphony composed through rigorous scientific exploration. An extensive repertoire of peer-reviewed studies, gracing the pages of prestigious journals such as The Lancet and Nature Communications, underscores the potential of stem cells to elevate transplant success rates. These studies illuminate advancements spanning from refining graft survival to hastening the regeneration of vital tissues, a resounding affirmation of the transformative capabilities underpinning stem cell-driven transplantation.
Embark on a Journey of Revelation
Eager to unravel the mysteries encapsulating stem cell-powered transplantation? We extend a heartfelt invitation to embark on an illuminating expedition through our comprehensive training courses in regenerative medicine. Enrich your understanding under the tutelage of eminent experts, delving into the most recent breakthroughs, evidence-based methodologies, and clinical applications. Step into a realm where the boundaries of medical possibilities are redrawn, where your perception of transplantation is enriched, and where you assume the mantle of a pioneer in the regenerative revolution.
The fusion of stem cells and organ transplantation isn’t confined to the realm of scientific speculation; it represents a monumental stride towards re-scripting the destinies of countless lives. As we venture into an epoch where medical accomplishments redefine our limits, the expedition becomes all the more exhilarating.
Join us at issca.us, where the convergence of science and hope awaits. Immerse yourself in the vanguard of regenerative medicine, where the transformative prowess of stem cells beckons. Together, we shall forge ahead, empowered by the symphony of possibilities, shaping a brighter, healthier future for generations to come.
- Published in Blog
ISSCA Announces the Lineup of Speakers for the Regenerative Medicine World Congress 2023
International Society for Stem Cell Application presents an unparalleled gathering of experts in Istanbul, Turkey.
Miami, Florida – The International Society for Stem Cell Application (ISSCA) is thrilled to unveil the remarkable roster of speakers for the highly anticipated Regenerative Medicine World Congress 2023. Set to take place from November 10 to 12, 2023, at the exquisite Crowne Plaza Istanbul Florya Hotel in Istanbul, Turkey, the congress is primed to be a convergence of minds dedicated to the advancement of stem cell therapy and regenerative medicine.
With over 35 countries represented, the Regenerative Medicine World Congress 2023 promises to be an extraordinary platform for knowledge exchange and scientific exploration. Distinguished doctors and scientists from across the globe will unite to discuss the latest developments in stem cell therapy and regenerative medicine through evidence-based research presentations.
Delegates attending the congress will have the unique opportunity to engage with more than 25 world-renowned medical experts who will present their insights and findings on a spectrum of issues related to this groundbreaking field. This three-day event is designed to foster interactive sessions, enabling attendees to deepen their understanding and broaden their perspectives on the applications of stem cell technology in various medical conditions.
Dr. Salih Yildirim, President of ISSCA, expressed his enthusiasm, saying, “I am delighted to witness the convergence of global medical experts in Istanbul. The Regenerative Medicine World Congress 2023 is an occasion to showcase our commitment to fostering international collaboration, sharing knowledge, and propelling medical progress.”
Echoing this sentiment, Benito Novas, an esteemed figure in the realm of regenerative medicine and the head of Public Relations for GSCG and ISSCA, highlighted ISSCA’s mission: “Our aim at ISSCA is to facilitate an environment of global collaboration and knowledge exchange. The Regenerative Medicine World Congress 2023 epitomizes this objective, offering a unique opportunity for professionals to engage in critical discussions, share insights, and collectively contribute to the advancement of medical science.”
A central highlight of the congress is the immersive hands-on training, facilitated by distinguished ISSCA-certified instructors. Participants will embark on an in-depth exploration of clinical and aesthetic applications of stem cell therapy during an intensive single-day workshop on November 12th. This comprehensive training, designed exclusively for those who secure the all-access package (limited to 20 seats), is guided by experts with extensive experience. Attendees are expected to acquire tangible skills that are readily applicable in their medical practice.
The congress will be inaugurated by Dr. Dayeong Kim from Korea and the President of ISSCA, Dr. Salih Yildirim. Their opening address will set the tone for an array of engaging sessions led by esteemed experts. Topics will span diverse medical conditions and real-world case studies, showcasing the application of stem cell therapy across various contexts.
Among the impressive lineup of speakers are luminaries such as:
– Dr. Dayeong Kim (Korea)
– Dr. Salih Yildirim (Turkey)
– Dr. Alan Gaveck (USA)
– Dr. Serdar Kabatas (Turkey)
– Dr. Yanti Kushmiran (Indonesia)
– Dr. Hilmi Karadeniz (Turkey)
– Dr. Roni Moya (Portugal)
– Dr. Tunç Akkoç (Turkey)
– Dr. Erdinc Civelek (Turkey)
– Dr. Mehmet Veli Karaaltın (Turkey)
– Dr. Ayman El Attar (USA)
– Prof. Utku Ates (Turkey)
– Dr. Fikrettin Şahin (Turkey)
– Dr. Emel Polat (Turkey)
– Dr. Patria Gonzalez (Dominican Republic)
– Dr. Ferda Alpaslan Pinarli (Turkey)
– Dra. Silvina Pastrana (Argentina)
– Dr. Samy Joheir (Belgium)
– Dr. Ahmet Doğan (Turkey)
– Dr. Jorge Elias (Argentina)
– Dr. Roland Neff (Switzerland)
– Prof. Aygen Türkmen (Turkey)
The Regenerative Medicine World Congress 2023 is an unparalleled opportunity for professionals to enrich their expertise, expand their network, and stay at the forefront of cutting-edge advancements in the field. To register and access detailed event information, please visit https://www.issca.us/turkey-world-conference-2023/
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in News
Global Stem Cells Group (GSCG) and Dr. Yanti Aesthetic Clinic Elevate Regenerative Medicine Landscape with New Stem Cell Center in Jakarta
Miami, Florida – Global Stem Cells Group (GSCG) is thrilled to announce the grand opening of its latest state-of-the-art Stem Cell Center, located in Jakarta, Indonesia. This momentous occasion marks a significant stride forward in the field of regenerative medicine and showcases GSCG’s commitment to providing innovative healthcare solutions worldwide.
In a groundbreaking partnership with the esteemed Dr. Yanti Aesthetic Clinic, GSCG introduces its third Stem Cell Center in Indonesia, complementing existing facilities in Surabaya and Bandung. Further underscoring their dedication to advancing medical research, GSCG also anticipates the unveiling of a fourth location in Bali in the near future.
The launch of the Stem Cell Center in Jakarta serves as a beacon of innovation, the International Society for Stem Cell Application (ISSCA), GSCG’s educational division, conducted a groundbreaking training session alongside Dr. Alan Gaveck. This session spotlighted the transformational potential of NK cell therapies in treating Cancer and Anti-aging concerns, further cementing GSCG’s pioneering influence.
A distinctive feature of this collaboration is the authorization granted to Dr. Yanti Aesthetic Clinic to leverage GSCG’s brand, technologies, products, and treatment protocols. Operating as a franchise, the center proudly carries the brand, adhering to meticulous organizational guidelines, while being owned and operated by Dr. Yanti Aesthetic Clinic. This symbiotic arrangement seamlessly merges shared expertise with individual ownership, fostering a harmonious blend of vision and innovation.
Beyond its role as a clinical hub, the newly inaugurated Stem Cell Center will also serve as a focal point for ISSCA’s training initiatives in Asia. In addition to the pioneering NK cell therapy training conducted at the clinic, the center will facilitate educational programs to empower medical professionals across the continent with cutting-edge insights and advancements in regenerative medicine.
Benito Novas, an esteemed figure in the realm of regenerative medicine and the head of Public Relations for GSCG and ISSCA, shared his insights during the inaugural event, stating, “Global Stem Cells Group is dedicated to democratizing regenerative medicine access on a global scale. We encourage physicians to embrace the clinical and aesthetic applications of stem cell therapy, enabling patients around the world to experience the transformative benefits of regenerative treatments.”
Reflecting on the journey that led to this momentous occasion, Novas continued, “Dr. Yanti and I met in Brussels back in 2018, when this ambitious endeavor was but a vision. Today, as we witness the fruition of that vision, I express my profound gratitude for the privilege of collaborating with Dr. Yanti Aesthetic Clinic in ushering in the future of regenerative medicine.”
Dr. Yanti Kushmiran, Director of the DR. Yanti Aesthetic Clinic, echoed these sentiments, stating, “Our partnership with GSCG, a trailblazer with over a decade of pioneering work, resonates deeply with our commitment to excellence. The establishment of our third Stem Cell Center in Indonesia under the esteemed Global Stem Cells Group brand strengthens our ability to provide enhanced services to our patients, ushering in a new era of regenerative healthcare.”
With the inauguration of the Stem Cell Center in Jakarta, GSCG and Dr. Yanti Aesthetic Clinic take a significant stride towards advancing regenerative medicine’s frontiers. This landmark collaboration is poised to shape the future of medical care, leveraging cutting-edge technologies and expertise to benefit patients across the Asian continent and beyond.
About Dr. Yanti Aesthetic Clinic:
Dr. Yanti Aesthetic Clinic is a revered healthcare institution renowned for its state-of-the-art aesthetic and regenerative treatments. With an unwavering dedication to excellence and a forward-thinking approach, Dr. Yanti Aesthetic Clinic is poised to shape the future of regenerative medicine in Indonesia and beyond.
About the International Society for Stem Cell Application (ISSCA):
The International Society for Stem Cell Application (ISSCA) serves as the educational arm of Global Stem Cells Group (GSCG), dedicated to promoting knowledge and expertise in stem cell therapy and regenerative medicine. ISSCA empowers medical professionals across the globe with essential insights and advancements in the field.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in News
Advancements in Hair Transplantation: A Paradigm Shift in Regenerative Medicine
In the realm of regenerative medicine, hair transplantation has experienced remarkable progress in recent years. As part of a multidisciplinary community of physicians and scientists dedicated to advancing the field, it is essential to stay informed about the latest developments in this area. This blog post aims to provide a comprehensive overview of the cutting-edge advancements in hair transplantation, highlighting the convergence of science, technology, and practice.
Tissue Engineering in Hair Transplantation:
The integration of tissue engineering principles into hair transplantation has opened new avenues for regenerative medicine. Scientists are actively exploring the use of biomaterials, growth factors, and scaffolds to create an optimal environment for transplanted hair follicles. By nurturing follicular cells, tissue engineering techniques hold immense potential in enhancing transplantation outcomes and promoting tissue regeneration.
Stem Cell-Based Approaches:
Stem cell therapy has emerged as a promising strategy within the realm of hair transplantation. Researchers are investigating the utilization of mesenchymal stem cells (MSCs) and adipose-derived stem cells (ADSCs) to stimulate hair follicle regeneration. These unique regenerative cells promote hair growth and significantly enhance the success rate of transplantation procedures. Ongoing research in stem cell-based therapies continues to unveil their potential to revolutionize hair restoration techniques.
Gene Therapy for Hair Loss:
Gene therapy is gaining traction as a cutting-edge approach to addressing hair loss at its core. Scientists aim to develop innovative treatments for both genetic and acquired forms of hair loss by manipulating genes involved in hair growth and regulation. Techniques such as CRISPR-Cas9 gene editing hold immense potential for altering gene expression associated with hair follicle development, offering personalized regenerative therapies.
Nanotechnology in Hair Transplantation:
Nanotechnology has paved the way for groundbreaking advancements in hair transplantation. Researchers are exploring the application of nanomaterials and nanoparticles to enhance the targeted delivery of growth factors, drugs, and stem cells directly to the hair follicles. This precise and controlled release optimizes the regenerative potential of transplanted hair follicles, leading to improved treatment outcomes and faster healing.
Artificial Intelligence (AI) and Machine Learning:
The integration of AI and machine learning algorithms has transformed various medical fields, including hair transplantation. AI-powered technologies assist in precise hair follicle extraction, optimizing graft placement, and predicting post-transplant outcomes. By analyzing vast datasets and patterns, AI algorithms enhance decision-making, improve surgical techniques, and contribute to personalized treatment plans in hair transplantation.
As active contributors to the advancement of regenerative medicine, staying informed about the latest developments in hair transplantation is crucial. Tissue engineering, stem cell-based approaches, gene therapy, nanotechnology, and the integration of AI and machine learning are reshaping the landscape of hair restoration. By remaining at the forefront of these advancements, physicians and scientists can harness the power of regenerative medicine to effectively treat hair loss and alleviate human suffering.
Join us at Issca.com and let us continue to collaborate, innovate, and explore the limitless potential of regenerative therapies.
- Published in Blog
Stem Cells and Diabetes: Exploring a Path to Improved Management
Diabetes is a chronic condition that affects millions of people worldwide. It occurs when the body cannot produce or use insulin properly, resulting in high blood sugar levels. Diabetes can cause serious complications such as heart disease, kidney failure, nerve damage, and vision loss.
There are two main types of diabetes: type 1 and type 2. Type 1 diabetes is an autoimmune disease that destroys the insulin-producing pancreatic beta cells. People with type 1 diabetes need to take insulin injections or use an insulin pump to manage their blood sugar levels. Type 2 diabetes is more common and occurs when the body becomes resistant to insulin or does not produce enough of it. People with type 2 diabetes can often control their blood sugar levels with diet, exercise, and oral medications.
However, these treatments are not always effective or sufficient for some people with diabetes. Moreover, they can have side effects such as weight gain, hypoglycemia, and gastrointestinal problems. Therefore, there is a need for alternative treatments that can restore the function of the pancreatic beta cells and provide a long-lasting cure for diabetes.
One of the most promising alternative treatments for diabetes is stem cell therapy. Stem cell therapy is a method of using various types of stem cells to replace or enhance the function of damaged or diseased cells in the body. Stem cells are undifferentiated cells that can develop into different types of specialized cells, such as muscle cells, nerve cells, or blood cells.
Stem cell therapy for diabetes aims to generate new insulin-producing beta cells from stem cells and transplant them into the pancreas or other sites in the body where they can secrete insulin in response to blood sugar levels. Different sources of stem cells can be used for this purpose, such as adult stem cells, or induced pluripotent stem cells.
Adult stem cells (ASCs) are found in various tissues and organs of the body and have the ability to differentiate into specific cell types related to their origin. For example, mesenchymal stem cells (MSCs) are ASCs that can be isolated from bone marrow, adipose tissue, or umbilical cord blood and can differentiate into bone, cartilage, fat, or muscle cells. MSCs have been shown to have immunomodulatory and anti-inflammatory properties that can protect the transplanted beta cells from immune attack or inflammation. MSCs can also secrete growth factors and cytokines that can stimulate the regeneration of endogenous beta cells or enhance the function of exogenous beta cells.
Induced pluripotent stem cells (iPSCs) are generated by reprogramming somatic cells (such as skin cells or blood cells) into a pluripotent state similar to ESCs using specific genes or factors. iPSCs can overcome the ethical and immunological issues of ESCs, as they do not require the use of embryos and can be derived from the patient’s own cells. iPSCs can also be genetically modified to correct any defects or enhance any features of the beta cells.
Several studies have demonstrated the feasibility and efficacy of stem cell therapy for diabetes in animal models and human trials. For example, a study by Rezania et al. (2014) reported that they were able to generate glucose-responsive insulin-secreting beta cells from human iPSCs using a seven-stage differentiation protocol. These beta cells were able to reverse diabetes in mice upon transplantation under the kidney capsule. Another study by Pagliuca et al. (2014) reported that they were able to produce large-scale batches of functional beta cells from human ESCs using a three-dimensional culture system and sequential modulation of key signaling pathways. These beta cells were also able to reverse diabetes in mice upon transplantation under the kidney capsule.
In conclusion, stem cell therapy for diabetes is a novel and promising alternative treatment that can potentially provide a permanent cure for this chronic condition by replacing or enhancing the function of insulin-producing beta cells. We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Blog
Global Stem Cells Group Announces New President of the International Society for Stem Cell Application (ISSCA)
Miami, Florida – Global Stem Cells Group, a leading organization in the field of regenerative medicine, is pleased to announce the appointment of Dr. Salih Yildirim as the new President of the International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group. Dr. Yildirim previously held the position of Director of Overseas Operations at ISSCA.
Dr. Salih Yildirim brings a wealth of experience and expertise to his new role as President of ISSCA. Having previously served as the Director of Overseas Operations, Dr. Yildirim has demonstrated his exceptional leadership skills and strategic vision throughout his career. He has played a vital role in expanding ISSCA’s international presence and fostering collaborations with stakeholders worldwide.
In a statement regarding the appointment, Dr. Daeyong Kim, the former President of ISSCA, expressed his confidence in Dr. Yildirim’s ability to lead the organization. Dr. Kim stated, “I think you are the best leader and the most prepared to be the President of ISSCA. Therefore, I think you should be the head of ISSCA.” Dr. Kim will now transition to other support functions within ISSCA.
Benito Novas, head of Public Relations for ISSCA, expressed his admiration for Dr. Salih Yildirim’s professional qualities. Novas said, “I have known and worked with Dr. Salih for more than 10 years, and I am honored to have him as President within the company. During these years, he has proven to be an exceptional leader with a great vision for ISSCA.”
ISSCA’s objectives under the leadership of Dr. Salih Yildirim will include advancing the understanding and application of stem cell therapies, promoting scientific research and collaboration among professionals in the field, and advocating for the ethical and responsible use of regenerative medicine worldwide. Dr. Yildirim’s extensive experience in business development, international relations, and regenerative medicine will undoubtedly contribute to the achievement of these objectives.
About Dr. Salih Yildirim:
Dr. Salih Yildirim holds a bachelor’s and master’s degrees in business administration from Cleveland State University (United States) and a Ph.D. in health management from the University of Health Sciences. He has held various key positions throughout his career, including Director of Overseas Operations at ISSCA. Dr. Yildirim is currently the General Manager of BioTrend Medical International, a biotechnology firm specializing in genetics, molecular biology, and stem cell technologies. He also serves as the chief executive officer of ReGen.IC Clinic, specializing in regenerative medicine and stem cell applications. Additionally, he is a member of the International Society for Stem Cell Application’s Board of Directors and the Global Stem Cell Group’s Board of Directors and International Operations Manager. Dr. Yildirim is also a member of Istanbul Atlas University’s Board of Directors. He is married and a proud father.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in News
